Inotek Pharmaceuticals Corp Share Price Nasdaq
Equities
US45780V1026
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
05-10 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
05-10 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |
Sales 2024 * | 26.32M 0 2.09B | Sales 2025 * | 163M 0 12.96B | Capitalization | 2.1B 0 166B |
---|---|---|---|---|---|
Net income 2024 * | -260M - -20.65B | Net income 2025 * | -219M - -17.4B | EV / Sales 2024 * | 72.3 x |
Net cash position 2024 * | 193M 0 15.33B | Net cash position 2025 * | 111M 0 8.86B | EV / Sales 2025 * | 12.2 x |
P/E ratio 2024 * |
-8.57
x | P/E ratio 2025 * |
-10.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.69% |
Latest transcript on Inotek Pharmaceuticals Corp
Managers | Title | Age | Since |
---|---|---|---|
Gaurav D. Shah
CEO | Chief Executive Officer | 49 | 03/01/18 |
Kinnari Patel
PSD | President | 46 | 03/01/18 |
Chief Tech/Sci/R&D Officer | 60 | 31/12/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pedro Granadillo
BRD | Director/Board Member | 77 | 03/01/18 |
Carsten Boess
BRD | Director/Board Member | 57 | 31/12/15 |
David Southwell
BRD | Director/Board Member | 63 | 31/07/14 |
1st Jan change | Capi. | |
---|---|---|
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |